Literature DB >> 27862920

Alternative designs for clinical trials in rare diseases.

Lusine Abrahamyan, Brian M Feldman, George Tomlinson, Marie E Faughnan, Sindhu R Johnson, Ivan R Diamond, Samir Gupta.   

Abstract

Evidence-based medicine requires strong scientific evidence upon which to base treatment. In rare diseases, study populations are often small, and thus this evidence is difficult to accrue. Investigators, though, should be creative and develop a flexible toolkit of methods to deal with the problems inherent in the study of rare disease. This narrative review presents alternative clinical trial designs for studying treatments of rare diseases, including cross-over and n-of-1 trials, randomized placebo-phase design, enriched enrollment, randomized withdrawal design, and classes of adaptive designs. Examples of applications of these designs are presented along with their advantages and disadvantages. Additional analytical considerations such as Bayesian analysis, internal pilots, and use of biomarkers as surrogate outcomes are further discussed. A framework for selecting appropriate clinical trial design is proposed to guide investigators in the process of selecting alternative designs for rare diseases.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Keywords:  Bayes theorem; adaptive trial design; clinical trials; cross-over studies; rare diseases

Mesh:

Year:  2016        PMID: 27862920     DOI: 10.1002/ajmg.c.31533

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  20 in total

Review 1.  Orphan drug development: the increasing role of clinical pharmacology.

Authors:  Mariam A Ahmed; Malek Okour; Richard Brundage; Reena V Kartha
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-07-23       Impact factor: 2.745

Review 2.  Public drug policy for children in Canada.

Authors:  Avram E Denburg; Wendy J Ungar; Mark Greenberg
Journal:  CMAJ       Date:  2017-07-31       Impact factor: 8.262

Review 3.  Potential immunotherapies for sarcoidosis.

Authors:  Van Le; Elliott D Crouser
Journal:  Expert Opin Biol Ther       Date:  2018-01-17       Impact factor: 4.388

4.  Rare disease specialists and clinical pharmacologists unite: Increase collection of longitudinal data!

Authors:  Gijs W E Santen; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2019-09-04       Impact factor: 4.335

Review 5.  Precision medicine for genetic epilepsy on the horizon: Recent advances, present challenges, and suggestions for continued progress.

Authors:  Juliet K Knowles; Ingo Helbig; Cameron S Metcalf; Laura S Lubbers; Lori L Isom; Scott Demarest; Ethan M Goldberg; Alfred L George; Holger Lerche; Sarah Weckhuysen; Vicky Whittemore; Samuel F Berkovic; Daniel H Lowenstein
Journal:  Epilepsia       Date:  2022-07-17       Impact factor: 6.740

6.  The Efficacy and Evidence-Based Use of Biologics in Children and Adolescents: Using Monoclonal Antibodies and Fusion Proteins as Treatments.

Authors:  Tim Niehues; Tuba Turul Özgür
Journal:  Dtsch Arztebl Int       Date:  2019-10-18       Impact factor: 5.594

7.  Current progress in the therapeutic options for mitochondrial disorders.

Authors:  E Koňaříková; A Marković; Z Korandová; J Houštěk; T Mráček
Journal:  Physiol Res       Date:  2020-11-02       Impact factor: 1.881

Review 8.  A systematic review of moral reasons on orphan drug reimbursement.

Authors:  Bettina M Zimmermann; Johanna Eichinger; Matthias R Baumgartner
Journal:  Orphanet J Rare Dis       Date:  2021-06-30       Impact factor: 4.123

9.  Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies.

Authors:  Andrea M Gross; Megan Frone; Karen W Gripp; Bruce D Gelb; Lisa Schoyer; Lisa Schill; Beth Stronach; Leslie G Biesecker; Dominic Esposito; Edjay Ralph Hernandez; Eric Legius; Mignon L Loh; Staci Martin; Deborah K Morrison; Katherine A Rauen; Pamela L Wolters; Dina Zand; Frank McCormick; Sharon A Savage; Douglas R Stewart; Brigitte C Widemann; Marielle E Yohe
Journal:  Am J Med Genet A       Date:  2020-01-08       Impact factor: 2.578

10.  Barriers and Facilitating Factors for Implementation of Genetic Services: A Public Health Perspective.

Authors:  Martina C Cornel; Carla G van El
Journal:  Front Public Health       Date:  2017-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.